

**Anti-IGF1R / CD221 Reference Antibody (teprotumumab)  
Recombinant Antibody  
Catalog # APR10191****Specification**

---

**Anti-IGF1R / CD221 Reference Antibody (teprotumumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P08069</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.64 KDa

**Anti-IGF1R / CD221 Reference Antibody (teprotumumab) - Additional Information****Target/Specificity**  
IGF1R / CD221**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-IGF1R / CD221 Reference Antibody (teprotumumab) - Protein Information****Name** IGF1R**Function**  
Receptor tyrosine kinase which mediates actions of insulin- like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway

is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGF1R through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.

**Cellular Location**

Cell membrane; Single-pass type I membrane protein


**Tissue Location**


Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.

**Anti-IGF1R / CD221 Reference Antibody (teprotumumab) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


**Anti-IGF1R / CD221 Reference Antibody (teprotumumab) - Images**




Anti-IGF1R / CD221 Reference Antibody (teprotumumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IGF1R / CD221 Reference Antibody (teprotumumab) is more than 96.97%, determined by SEC-HPLC.



Immobilized human IGF1R His at 2 µg/mL can bind Anti-IGF1R / CD221 Reference Antibody (teprotumumab)  $EC_{50}=0.009199$  µg/mL



Human IGF1R CHO-K1 cells were stained with Anti-IGF1R / CD221 Reference Antibody (teprotumumab) and negative control protein respectively, washed and then followed by APC and analyzed with FACS, EC<sub>50</sub>=0.1968 nM